Future of Regulation of Genetic Information, Especially Whole Genome Sequencing-Professor Hank Greely-01/10/2012 - 6:00pm

Event Information
Event Topic: 
Future of Regulation of Genetic Information, Especially Whole Genome Sequencing
Event Date: 
01/10/2012 - 6:00pm
Event Location: 
Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA
Speaker Information
Event Speaker: 
Professor Hank Greely
Event Speaker Title: 
Chair of California’s Human Stem Cell Research Advisory Committee
Event Speaker Company: 
Stanford University
Event Speaker Bio: 

Prof. Hank Greely

Hank Greely is the Deane F. and Kate Edelman Johnson Professor of Law and Professor, by courtesy, of Genetics at Stanford University. He specializes in ethical, legal, and social issues arising from advances in the biosciences, particularly from genetics, neuroscience, and human stem cell research. He chairs the California Advisory Committee on Human Stem Cell Research and the steering committee of the Stanford University Center for Biomedical Ethics, and directs the Stanford Center for Law and the Biosciences. From 2007 to 2010 he was a co-director of the Law and Neuroscience Project. In 2006, he was elected a fellow of the American Association for Advancement of Science.

Professor Greely graduated from Stanford in 1974 and from Yale Law School in 1977. He served as a law clerk for Judge John Minor Wisdom on the United States Court of Appeals and for Justice Potter Stewart of the United States Supreme Court. After working during the Carter Administration in the Departments of Defense and Energy, he entered private practice in Los Angeles in 1981 as a litigator with the law firm of Tuttle & Taylor, Inc. He began teaching at Stanford in 1985.

Event Details
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Event Details: 

The world of human genetics, both in research and in clinical practice, is about to move fully into the era of whole genome sequencing. This quantitative change in the amount of DNA sequenced will lead to qualitative changes in the challenges researchers and clinicians face. Some of those challenges will be ethical, some will be regulatory, and all will be of great practical important. This talk will describe those challenges and some promising ways to respond to them.